$AVXL News

Anavex Life Sciences Receives Expected Delinquency Notification From Nasdaq

CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus

Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer

What Makes Anavex Life Sciences (AVXL) One of the Best Shorted Penny Stocks

Anavex Life Sciences Teases New Pivotal Blarcamesine Trials, Maps Regulatory Path at Needham Conference

Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease

Anavex Life Sciences Announces New Findings On The Shared Biology Between Autism Spectrum Disorder And Alzheimer's Disease

Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference

Anavex Life Sciences Provides Comprehensive Regulatory Update

Anavex Life Sciences Submits Additional Data To FDA With Objective To Discuss Potential Pathways Towards NDA For Treatment Of Early Alzheimer's Disease

Anavex Life Sciences Continues Dialogue With EMA To Advance Development Program Of Oral Blarcamesine In Early Alzheimer's Disease

Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip?

Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback

Anavex Life Sciences shares are trading lower after the company announced that it withdrew its application for European Medicines Agency marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer's disease in adults.

Anavex Withdraws EU Filing For Alzheimer's Treatment After Regulator Feedback

Anavex Life Sciences shares are trading higher after the company presented its new data from its AD-004 phase IIb/III trial at the AD/PD 2026 conference demonstrating consistent correlation between the treatment effect of oral blarcamesine and preservation of brain volume in early alzheimer's disease.

Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease

Anavex Life Sciences Presents New Data Of Blarcamesine At AD/PD 2026 Conference; Data Show Brain-Volume Preservation Correlates With Patient Outcomes